


Accepted Manuscript

Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Laura Poupon, Sylvain Lamoine, Vanessa Pereira, David A. Barriere, Stéphane Lolignier, Fabrice Giraudet, Youssef Aissouni, Mathieu Meleine, Laëtitia Prival, Damien Richard, Nicolas Kerckhove, Nicolas Authier, David Balayssac, Alain Eschalier, Michel Lazdunski, Jérôme Busserolles



PII: S0028-3908(18)30404-0

DOI: [10.1016/j.neuropharm.2018.07.026](https://doi.org/10.1016/j.neuropharm.2018.07.026)

Reference: NP 7276

To appear in: *Neuropharmacology*

Received Date: 19 April 2018

Revised Date: 20 July 2018

Accepted Date: 23 July 2018

Please cite this article as: Poupon, L., Lamoine, S., Pereira, V., Barriere, D.A., Lolignier, Sté., Giraudet, F., Aissouni, Y., Meleine, M., Prival, Laë., Richard, D., Kerckhove, N., Authier, N., Balayssac, D., Eschalier, A., Lazdunski, M., Busserolles, Jéô., Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin, *Neuropharmacology* (2018), doi: 10.1016/j.neuropharm.2018.07.026.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Research Article:

Title: Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Authors: Laura POUPON^{1*}, Sylvain LAMOINE^{1*}, Vanessa PEREIRA¹, David A. BARRIERE¹, Stéphane LOLIGNIER¹, Fabrice GIRAUDET¹, Youssef AISSOUNI¹, Mathieu MELEINE¹, Laëtitia PRIVAL¹, Damien RICHARD¹, Nicolas KERCKHOVE^{1,2}, Nicolas AUTHIER^{1,2}, David BALAYSSAC^{1,2}, Alain ESCHALIER^{1,2§}, Michel LAZDUNSKI^{3,4§}, Jérôme BUSSEROLLES^{1,2§}.

Affiliations:

¹ *Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, Neuro-Dol, F63000, Clermont-Ferrand, France*

² *Institut Analgesia, Faculté de Médecine, BP38, 63001, Clermont-Ferrand, France*

³ *Université de Nice Sophia Antipolis, 06560 Valbonne, France*

⁴ *CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, 660 Route des Lucioles Sophia Antipolis, 06560 Valbonne, France.*

*These authors contributed equally to the work

Number of text pages of the entire manuscript: 26

Number of figures: 7

(§) Correspondence:

Pr Eschaliér, Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, Neuro-Dol, F63000, Clermont-Ferrand, France

email : alain.eschaliér@uca.fr ; tel 33(0) 4 73 17 82 30 ; fax 33(0) 4 73 27 71 62

Pr Lazdunski, CNRS, IPMC, UMR 7275, 660 Route des Lucioles Sophia Antipolis, 06560 Valbonne, France

Download English Version:

<https://daneshyari.com/en/article/8516199>

Download Persian Version:

<https://daneshyari.com/article/8516199>

[Daneshyari.com](https://daneshyari.com)